Glucosamine hydrochloride specifically inhibits COX-2 by preventing COX-2 N-glycosylation and by increasing COX-2 protein turnover in a proteasome-dependent manner.
COX-2 and its products, including prostaglandin E(2), are involved in many inflammatory processes. Glucosamine (GS) is an amino monosaccharide and has been widely used for alternative regimen of (osteo) arthritis. However, the mechanism of action of GS on COX-2 expression remains unclear. Here we describe a new action mechanism of glucosamine hydrochloride (GS-HCl) to tackle endogenous and agonist-driven COX-2 at protein level. GS-HCl (but not GS sulfate, N-acetyl GS, or galactosamine HCl) resulted in a shift in the molecular mass of COX-2 from 72-74 to 66-70 kDa and concomitant inhibition of prostaglandin E(2) production in a concentration-dependent manner in interleukin (IL)-1beta-treated A549 human lung epithelial cells. Remarkably, GS-HCl-mediated decrease in COX-2 molecular mass was associated with inhibition of COX-2 N-glycosylation during translation, as assessed by the effect of tunicamycin, the protein N-glycosylation inhibitor, or of cycloheximide, the translation inhibitor, on COX-2 modification. Specifically, the effect of low concentration of GS-HCl (1 mM) or of tunicamycin (0.1 microg/ml) to produce the aglycosylated COX-2 was rescued by the proteasomal inhibitor MG132 but not by the lysosomal or caspase inhibitors. However, the proteasomal inhibitors did not show an effect at 5 mM GS-HCl, which produced the aglycosylated or completely deglycosylated form of COX-2. Notably, GS-HCl (5 mM) also facilitated degradation of the higher molecular species of COX-2 in IL-1beta-treated A549 cells that was retarded by MG132. GS-HCl (5 mM) was also able to decrease the molecular mass of endogenous and IL-1beta- or tumor necrosis factor-alpha-driven COX-2 in different human cell lines, including Hep2 (bronchial) and H292 (laryngeal). However, GS-HCl did not affect COX-1 protein expression. These results demonstrate for the first time that GS-HCl inhibits COX-2 activity by preventing COX-2 co-translational N-glycosylation and by facilitating COX-2 protein turnover during translation in a proteasome-dependent manner.
Jang
Byeong-Churl
BC
Chronic Disease Research Center and Institute for Medical Science, Keimyung University School of Medicine, Daegu, South Korea. jangbc12@kmu.ac.kr
Sung
Su-Haeng
SH
Park
Jong-Gu
JG
Park
Jong-Wook
JW
Bae
Jae Hoon
JH
Shin
Dong Hoon
DH
Park
Gi-Young
GY
Han
Seung-Bum
SB
Suh
Seong-Il
SI
D045744:Cell Line, Tumor; D002712:Chlorides / Q000737:chemistry*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D015232:Dinoprostone / Q000378:metabolism; D004848:Epithelium / Q000378:metabolism; D005688:Galactosamine / Q000737:chemistry; D005944:Glucosamine / Q000737:chemistry* / Q000502:physiology*; D006031:Glycosylation; D006801:Humans; D007249:Inflammation; D053583:Interleukin-1beta / Q000378:metabolism; D008168:Lung / Q000378:metabolism; D008954:Models, Biological; D010003:Osteoarthritis / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism*
D002712:Chlorides; D053583:Interleukin-1beta; D005688:Galactosamine; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D046988:Proteasome Endopeptidase Complex; D015232:Dinoprostone; D005944:Glucosamine